Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram for Post-Treatment Lyme Disease Symptoms
NCT03891667Phase 2Completed
- Sponsor
- Research Foundation for Mental Hygiene
- Start
- Jul 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of disulfiram in post-treatment Lyme disease syndrome (PTLDS) (2 arms), sponsored by Research Foundation for Mental Hygiene. Primary endpoints: Fatigue Severity Scale at 10 weeks and Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form at 10 weeks. Started Jul 2019; status: completed.
02
Drugs
disulfiram
03
Conditions
post-treatment Lyme disease syndrome (PTLDS)
Beyond the preview
Go deeper on NCT03891667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891667.